Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87).
Blood Glucose
/ drug effects
Chlorpropamide
/ administration & dosage
Diabetes Mellitus, Type 2
/ blood
Drug Substitution
Drug Therapy, Combination
Female
Follow-Up Studies
Glyburide
/ administration & dosage
Glycated Hemoglobin
/ drug effects
Humans
Hypoglycemic Agents
/ administration & dosage
Insulin
/ administration & dosage
Male
Metformin
/ therapeutic use
Middle Aged
Precision Medicine
/ methods
Prognosis
Risk Factors
Time Factors
Treatment Outcome
United Kingdom
Durability
Glucose-lowering agents
Modelling
Monotherapy failure
Precision medicine
Journal
Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
14
04
2020
revised:
27
06
2020
accepted:
13
07
2020
pubmed:
24
7
2020
medline:
29
10
2020
entrez:
24
7
2020
Statut:
ppublish
Résumé
Predicting likely durability of glucose-lowering therapies for people with type 2 diabetes (T2D) could help inform individualised therapeutic choices. We used data from UKPDS patients with newly-diagnosed T2D randomised to first-line glucose-lowering monotherapy with chlorpropamide-glibenclamide-basal insulin or metformin. In 2339 participants who achieved one-year HbA Follow-up was median (IQR) 11.0 (8.0-14.0) years. Monotherapy-failure occurred in 72%-82%-75% and 79% for those randomised to chlorpropamide-glibenclamide-basal insulin or metformin respectively-after median 4.5 (3.0-6.6)-3.7 (2.6-5.6)-4.2 (2.7-6.5) and 3.8 (2.6- 5.2) years. Time-to-monotherapy-failure was predicted primarily by HbA Post one-year glycaemic durability can be predicted robustly in individuals with newly-diagnosed T2D who achieve HbA
Identifiants
pubmed: 32702468
pii: S0168-8227(20)30585-4
doi: 10.1016/j.diabres.2020.108333
pii:
doi:
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
hemoglobin A1c protein, human
0
Metformin
9100L32L2N
Glyburide
SX6K58TVWC
Chlorpropamide
WTM2C3IL2X
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
108333Subventions
Organisme : Medical Research Council
ID : MR/N00633X/1
Pays : United Kingdom
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.